Life Sciences

Given the importance of the changes from PPACA and the creation of the health insurance marketplaces, we are providing our online Frost.com blog on HIX in collected form for the month of August for ease of use by our subscription clients. This discussion is brought to you by our Connected Health research program. Please also follow our blog, part o...

The global human plasma-derived therapeutics market is expected to experience a surge in demand due to an increase in the awareness of diseases and therapeutic options. The plasma-derived therapeutics market is segmented into albumin, immunoglobulins, coagulation factors, and other haemotologicals. The segments are discussed with supporting informa...

The overall research objective was to capture and analyze global next-generation (NGS) sequencing trends and use. Most researchers outsource NGS technologies; however, in-house NGS technology use is expected to increase within the next 12 months. Data accuracy and operating costs are the top criteria for purchasing sequencing instruments. Disease-r...

This issue of Vital Signs, released on August 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, Advanced Medical Technology and Connected Health.

This research service presents an overview and analysis of the Latin American Contract Research Organization (CRO) market with a focus on Argentina, Brazil, and Mexico. It provides country revenue by phase, therapeutic type, and region. The study discusses key challenges and emerging market trends, while providing detailed information on support se...

The IVD market in China presents diversified growth potential for different tiers of participants: domestic participants stand to gain from the growth momentum in the lower-end market, whereas foreign leading manufacturers dominate the high-end market. This research service analyzes the IVD market and provides forecasts and opportunities by underst...

This issue of Vital Signs, released on July 31, 2013, provides an analysis of sequestration measures that were in effect March 1st, 2013 on academic and government laboratory spending on life science research tools and products. Additionally, a company spotlight is provided for BioScale in Lexington, MA. The company provides a highly innovative pr...

This issue of Vital Signs, released on July 31, 2013, discusses perspectives of different Frost & Sullivan analysts on recent noteworthy news items for various markets including Pharma/Biotech, In Vitro Diagnostics, Advanced Medical Technology and Connected Health.

This research service offers an assessment for marketed and pipeline products for the global ACS therapeutics market. Segmentation by drug class is provided along with additional supporting information such as clinical trial timelines and results, historical and projected launch timelines, and epidemiology. The marketed and pipeline products are br...